AAV8介导的基因治疗可挽救Tlcd3b敲除小鼠模型的视网膜变性表型
本研究在Tlcd3b-/-小鼠视网膜变性模型中,于出生后第21天(P21)和第120天(P120)以不同剂量行视网膜下注射rAAV8-hGRK1-Tlcd3b,评估基因替代疗法疗效。Tlcd3b过表达可显著改善光感受器功能并保留光感受器细胞,效果持续1年;光感受器细胞特异性表达Tlcd3b足以挽救表型,提示TLCD3B主要在光感受器中发挥功能。突变视网膜中C16-、C18-和C20-神经酰胺减少,Tlcd3b过表达后恢复,支持TLCD3B为神经酰胺合酶。
要点
- Tlcd3b过表达可显著改善Tlcd3b-/-小鼠光感受器功能并保留光感受器细胞,效果持续1年。
- 光感受器细胞特异性表达Tlcd3b足以挽救表型,提示TLCD3B主要在光感受器中发挥功能。
- 突变视网膜中C16-、C18-和C20-神经酰胺减少,Tlcd3b过表达后恢复,支持TLCD3B为神经酰胺合酶。
核心结论
- 研究证明基因治疗对Tlcd3b突变视网膜具有治疗疗效,为开发TLCD3B视网膜病变的未来疗法奠定基础。
研究设计与样本
- 使用Tlcd3b-/-小鼠作为遗传性视网膜疾病动物模型,行视网膜下注射rAAV8-hGRK1-Tlcd3b以评估基因替代疗法疗效。
- Tlcd3b-/-小鼠在出生后第21天(P21)和出生后第120天(P120)两个时间点接受不同剂量治疗。
主要发现
- Tlcd3b过表达挽救了突变小鼠的视网膜变性,表现为光感受器功能显著改善且光感受器细胞在1年观察期内得以保留。
- 尽管Tlcd3b在视网膜所有细胞类型中表达,光感受器细胞特异性表达Tlcd3b足以挽救表型,提示TLCD3B主要在光感受器中发挥功能。
- 突变视网膜的质谱分析显示C16-、C18-和C20-神经酰胺减少,Tlcd3b过表达后这些神经酰胺恢复,与TLCD3B为神经酰胺合酶的观点一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to assess the therapeutic efficacy of rAAV8-hGRK1-Tlcd3b in a Tlcd3b-/- mouse model of retinal generation and validate TLCD3B's role as a ceramide synthase in vivo. METHODS: Using Tlcd3b-/- mice as an inherited retinal disease animal model, we performed subretinal injection of rAAV8-hGRK1-Tlcd3b and evaluated the efficacy of gene replacement therapy. Tlcd3b-/- mice were treated at two time points: postnatal day 21 (P21) and postnatal day 120 (P120) with various dosages. RESULTS: Tlcd3b overexpression rescued retinal degeneration in the mutant mice, as indicated by significantly improved photoreceptor function and preservation of photoreceptor cells over the course of 1 year. Although Tlcd3b is expressed in all cell types in the retina, photoreceptor cell-specific expression of Tlcd3b is sufficient to rescue the phenotype, indicating the primary function of TLCD3B is in photoreceptors. Consistent with the idea that TLCD3B is a ceramide synthase, mass spectrometry analyses of the mutant retina indicate the reduction of C16-, C18-, and C20-ceramides in the retina, which are restored with Tlcd3b overexpression. CONCLUSIONS: Our findings demonstrated the therapeutic efficacy of gene therapy in treating Tlcd3b mutant retina, laying the foundation for developing future therapy for TLCD3B retinopathy.
引用
- Qian X, Liu H, Fu S, et al. AAV8-Mediated Gene Therapy Rescues Retinal Degeneration Phenotype in a Tlcd3b Knockout Mouse Model. Invest Ophthalmol Vis Sci. 2022. PMID: 35275174. doi:10.1167/iovs.63.3.11
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。